Results of the study suggest that LNRRIL6 may act as an IL‐6 promoter through the IL‐6–STAT3 pathway; however, its utilization as a potential biomarker and therapeutic target for CRC warrants further clinical validation. Here, STAT3 is linked to colorectal carcinoma.